CDllb is the a chain of the Mac-l integrin and is preferentially expressed in myeloid cells (neutrophils, monocytes, and macrophages). We have previously shown that the CD1 1 b promoter directs cell-type-specific expression in myeloid lines using transient transfection assays. To confirm that these promoter sequences contain the proper regulatory elements for correct myeloid expression of CDllb in vivo, we have used the -1.7-kb human CDllb promoter to direct reporter gene expression in transgenic mice. Stable founder lines were generated with two different reporter genes, a Thy 1 .l surface marker and the Escherichia coli l a d (@-galactosidase) gene. Analysis of founders generated with URING HEMATOPOIESIS, immature myeloid progenitor cells undergo a program of differentiation that results in the production of mature neutrophils and monocytes; the latter subsequently undergo further maturation into macrophages.' Normal differentiation is accompanied by distinct changes in gene expression. The importance of understanding this process is underscored by the finding that most adult acute leukemia is characterized by a block in the differentiation program.'
moter can direct high-level expression of heterologous reporter genes in murine macrophages.
MATERIALS AND METHODS
Construction of the CD1 lb/Thyl. 1 and CD1 lb/P-gal transgenes. The CD1 l b promoter fragment used in these studies extended from bp -1704 to +83 and therefore included 83 bp of the 5' untranslated region extending up to the ATG start codon (Fig lA) .'.*" This genomic fragment was subcloned from a CD1 l b genomic A clone2' into pGEM3zf-, isolated by restriction endonuclease digestion with HindIII and Sma I, and subsequently ligated into the HindIIVEcoRV sites of pBluescript KS (pKS). A 2.1-kb BamHVNot I fragment containing the human growth hormone (HGH) gene was inserted into the BamHVNot I sites of pKS to create pB202. Finally, a 544-bp BamHI fragment containing the murine Thyl.1 cDNA was inserted into the BamHI site of pB202 to produce pB203, containing the -1.7-kb CD1 l b promoter 5' of the Thyl.1 cDNA and hGH gene in pKS (Fig 1B) . To synthesize a CD1 l b reporter construct using an alternative reporter, the HindIIYSma I CD1 1 b fragment was blunt end ligated into the Hind111 site of pSDKlacZpA*' to form plasmid T133, containing the -1.7-kb CD1 l b promoter 5' of the lacZ gene ( Fig 1C) . 
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2.0 kb probe from pSDKlacZpA Distal to the Thyl.1 cDNA is a 2.1-kb 6amHIINot I fragment containing the human growth hormone gene, which serves to provide splice donorlacceptors sites to enhance transgene expressionu as well as a polyadenylation signal. Exons in tha HGH gena are presented as boxes. DNA was isolated after digestion with ffimllll and Not I before injection into embryos for production of the transgenic line. The probe used for Southern blot analysis of founder copy number was the 544-bp B s m H l fragment containing the Thyl.1 cDNA. (C) @-gal reporter. The 1,787-bp CDllb promoter was blunt end ligated into the plasmid pSDKlacZpA, which contains the l a d gene encoding p-galactosidase." At the 3' end of the p-gal coding region is an SV40-derived splice donorlacceptor and polyadenylation site. Shown are the locations of the single 6amHl site in the construct (6amHI was used to linearize the plasmid pSDKbcZpA as a standard on Southern blots), the other Sst I sites in the transgenic construct, as well as the location of the 2.0-kb Sst I fragment from pSDKlacZpA used as a probe. Also shown are the Cla I and EcoRV sites used to generate the probe used in RNAse protection asaeyz, as well as the location of the PCR primers (PCR 5' and PCR 3') used for screening founder animals. The Hindlll/6amHl fragment was isolated and used to generate transgenic founders.
Production oftransgenic mice. The CDllblThyl.1 and CD1 lbl p-gal transgenes were isolated away from vector sequences by digestion with HindIIVNot I and HindIIVBamHI, respectively, followed by agarose gel electrophoresis. DNA fragments were then purified by electroelution or glass bead extraction. Transgenic mice were generated by microinjection into male pronuclei of single-cell embryos and reimplantation into pseudopregnant recipient females. CD1 lbRhy1.1 transgenics were established in C57BL mice, which are homozygous for the Thyl.2 allele, whereas the CD1 1 blp-gal mice were established in the FVB line, which is homozygous for the Thy l .l allele.
In the case of the CD 1 1 blp-gal construct, founders were identified first by polymerase chain reaction (PCR) of tail snip DNA, using as primers 5'-ATACGCCGAACGATCGCCAGlTCT-3' and 5'-CACTACGCGTACTGTGAGCCAGAG-3', representing bp 178 I -1804 and 2103-2080 of the lacZ gene, respectively.** PCR-positive CD1 lblp-gal mice were confirmed and CD1 1 blThyl. 1 mice were identified by Southern blot analysis as described below.
Assessment of transgene copy number by Southern blot analysis. Confirmation of integration of the transgene and assessment of copy number was performed by Southern blot. Genomic DNA was prepared from tails of mice by digestion overnight with 100 pg/mL of proteinase K in 10 mmolL Tris, pH 8.0, 100 m m o K NaCI, 10 m o l L EDTA, and 0.5% sodium dodecyl sulfate (SDS). The DNA was then extracted with a mixture of 50:48:2 pheno1:chloroformisoamyl alcohol and ethanol-precipitated. Ten micrograms of DNA was then cut to completion overnight with the restriction enzymes as described in the legend to Fig 2, L KHCO,, 0.1 mmol/L EDTA followed by washing in phosphatebuffered saline (PBS). Peritoneal cells were isolated by peritoneal lavage with 20 mL PBS at times indicated after the intraperitoneal administration of I mL of a 10% solution of thioglycollate (DIFCO, Detroit, MI). Bone marrow was flushed from femurs and tibias with PBS. Assessment of cell morphology of bone marrow and peritoneal cells was performed by Wright-Giemsa staining of slides after cytocentrifugation. CD5' (B-l) B cells were isolated from peritoneal cells of non-thioglycollate-treated animals as described," using a combination of T-cell complement-mediated lysis, depletion of macrophages by adherence, removal of residual macrophages and other nonlymphoid cells by sedimentation on discontinuous Percoll gradients, and removal of CDY (B-2) B cells with antimouse CD23 antibodies and magnetic depletion. In a second set of experiments, CD5' R cells were isolated by T-cell depletion, adherence, and Percoll sedimentation, followed by fluorescence-activated cell sorting (FACS) with CD5 monoclonal antibodies (MoAbs). These cells were 99.1% IgM'. CD5-(B-2) B cells were isolated in a similar manner from splenocytes, except that contaminating CD5' B cells were removed by magnetic particles. pSDKlacZpA. "P-gal" on the left indicates the position of the 2.7-kb Sst I fragment from the transgene (Fig 1C) . The blot was exposed for 52 hours with an intensifying screen.
Analysis
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Transgenic sorting on a Becton Dickinson FACStar''"' sorter (Becton Dickinson, Mountain View, CA). Antibodies used included Gr-l FITC (RB6-8C5; Pharmingen, San Diego, CA) recognizing a granulocytic markef that increases with maturation*'; Mac-1 F'ITC (Caltag) recognizing mouse CDllb; Thyl.1 PE (Serotec; Harlan Bioproducts for Science, Indianapolis, IN), CD5 (Becton Dickinson), and B220, CD4, and CD8 (all from Caltag, South San Francisco, CA). In some experiments, dead cells were removed from analysis using 1 pg/ mL propidium iodide; because greater than 95% of cells in most experiments were viable, this procedure did not significantly change any of the results obtained.
Isolation of RNA from murine tissues. Total RNA was isolated from murine tissues by homogenization in a tissue homogenizer (Brinkmann, Westbury, NY) in 4 m o m guanidium isothiocyanate, 17 m o V L sarkosyl, 250 mmol/L sodium citrate, pH 7.0, and 0.1% p mercaptoethanol, followed by cesium chloride centrif~gation.?~ Total RNA was isolated from murine macrophages by adding the guanidium solution to the pelleted cells and vortexing as quickly as possible, omitting the tissue homogenization step.
Northern blot analysis. Ten micrograms of total RNA was fractionated on either 1.2% or 1% formaldehyde/agarose gels, as indicated in the figure legends, and transferred by capillary blotting to nylon membranes (Biotrans; ICN, Irvine, CA). Membranes were baked at 80°C for 1 hour and UV cross-linked as described above. Blots were prehybridized, hybridized, and washed as described above for Southern blots. The probes were either the 544-bp Thyl .l cDNA (Fig 1B) or a mouse Mac-l cDNA probe." Autoradiography was performed at -80°C with an intensifying screen for the time indicated in each figure legend. Blots were then hybridized to an [cx-~*P]-~CTP 3' end-labeledZ9 18s oligonucleotide probe overnight in 6 x SSC, 5X Denhardt's solution and 0.5% SDS at 48°C; washed twice in 2X SSC and 0.2% SDS at room temperature for 5 minutes; and washed once in 0.2X SSC and 0.2% SDS at 48°C for 30 minutes. The oligonucleotide probe for 18s rRNA was bp 938 to 921 of the human 18s ribosomal RNA gene, 5'-TCGGGCCTGCT'ITGAACA-3'"' Intensity of bands was quantitated using Imagequant phosphorimager software (Molecular Dynamics).
X-gal staining of cells for detection of P-galactosidase activity. Peritoneal cells were washed in PBS, fixed in 0.75% formaldehyde, 0.05% glutaraldehyde, washed in PBS plus 2 mmol/L MgCI2, and incubated in 7 mmol/L K,Fe(CN),, 7 mmol/L &Fe(CN),, 2 mmol/ L MgCI2, 0.02% NP-40, and 1 mg/mL Xgal (diluted from a 2% stock in N,N-dimethylformamide [DMF]).2' In general, the best discrimination between transgenic and nontransgenic expression was obtained after 8 to 18 hours at 37°C.
RNAse protection assay ,for lac2 mRNA. A plasmid containing a 290-bp fragment of the Escherichia coli lacZ gene, corresponding to bp 836 to 1125," was cloned into the Cla IIEcoRV sites of the plasmid pBluescript 11 KS+. The plasmid was linearized with Xho I, and a 378-bp antisense probe labeled with a"P-UTP was generated by incubation of I pg of linearized plasmid with 20 U T7 polymerase as described." The probe was purified on 6% acrylamide gels. A total of 5 X 10' cpm (specific activity, 2.8 X IO' cpm/pg) of probe was incubated with 20 pg of total RNA for 16 hours at 45°C in 80% formamide, 400 mmoliL NaCI, 1 rnmol/L EDTA. Singlestranded RNA was digested by incubation with 200 pg/mL RNAse A and 2 U RNAse TI. Products were separated on a 6% acrylamidd 7 rnol/L urea gel, dried, and autoradiographed. Size standards used were Msp 11-digested pBR322 DNA fragments end-labeled using T, polynucleotide kinase and y3*P-ATP. promoter was placed in front of the E coli lacZ gene, which can be easily assayed by staining for ,&galactosidase activity using Xgal as a substrate. We chose this as an alternate reporter because previous investigators had shown its utility in analysis of the activity of the platelet factor 4 promoter in hematopoietic cells."
RESULTS
Generation
These two different constructs were used to generate transgenic founder mice, which were then bred to establish stable lines. We were able to derive three founder lines heterozygous for the transgene that were analyzed in this study.
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The single Thy 1.1 reporter line had an estimated copy number of S genome equivalents as estimated by Southern blot analysis (Fig 2A) , whereas the two 0-gal reporter lines had estimated copy numbers of 1 for founder no. 20 and 5 for founder no. 33, respectively (Fig 2B and C) .
The CDIIh promoter directs high-level expression of reporter genes in macrophages in transgenic mice. We first screened for expression of the Thy 1.1 founder by measuring the surface expression of the Thyl.1 reporter in peritoneal macrophages. FACS analysis of these cells, which are greater than 90% macrophages and express high levels of murine CD1 l b (Mac-l) (Fig 3) , demonstrated very high levels of the Thyl.1 epitope, which was not present on cells from the nontransgenic littermate, which expresses only the endogenous Thyl.2 antigen (Fig 3) . To assess the relative level of RNA produced by the CD1 Ib promoter in comparison to the endogenous murine CD1 Ib promoter, we per-
. . formed Northern blot analysis (Fig 4) . Because the Thy1 .l and Thy1.2 antigens differ by only one amino acid, both RNAs are detected simultaneously in Northern blots. The transgenic Thyl . l RNA can be distinguished from the endogenous Thyl.2 RNA, which is slightly greater in size. Although we could detect no Thyl mRNA in peritoneal macrophages from nontransgenic littermates (Fig 4A, lane  l) , a very high level of expression was observed in the CD1 1bRhy1.1 animal (Fig 4A, lane 2) . We compared the amount of RNA expressed in the transgene with that of the endogenous CD1 1 b gene in macrophages (Fig 4B, lane 9) by densitometry of the signal on Northern blots and correcting for the time of exposure, intensity of the 18s signal, and copy number. We estimate by this analysis that the transgene expresses at approximately two thirds the strength of the endogenous mouse CD1 l b gene at the RNA level. Significant levels of the transgene RNA could also be detected in bone marrow and spleen, as well as to a lesser degree in lung (it should be noted that the blot in Fig 4A was exposed for only 3.5 hours). We were unable to detect significant levels of the transgene RNA in other tissues sampled, including kidney and thymus, even after long exposure of the blot. As expected, we observed high levels of the endogenous Thyl RNA in brain and thymus. This pattern of transgenic RNA expression is similar to that observed with the endogenous murine CD1 I b gene, in which high levels are observed in macrophages and bone marrow and lesser amounts in spleen (Fig 4B) .
We also observed high levels of reporter gene expression in both &gal founder lines examined. An example of the Xgal staining observed in peritoneal macrophages from founder no. 20 is demonstrated in Fig 5. A faint blue color can be observed in peritoneal macrophages from nontransgenic littermates (Fig SA) , which presumably reflects The bottom panel shows hybridization t o the 18s oligonucleotide autoradiogram was exposed for 16 hours with an intensifying screen.
(exposed for 30 minutes with a screen).
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For personal use only. on October 30, 2017. by guest www.bloodjournal.org From some endogenous P-galactosidase-like activity. This color did not deepen with longer incubation times. The blue staining of the CD1 IblP-gal macrophages is far more intense in color (Fig SB) . A similar increase in @-gal activity compared with that in nontransgenic macrophages was noted with founder no. 33 as well, although the intensity of staining was less than that of founder no. 20, even though founder no. 33 was estimated to harbor 5 times as many copies. Almost all (90%) of the peritoneal cells in these cultures appear to be macrophages on the basis of morphology after Wright-Giemsa staining. We also used FACS to separate these peritoneal cells into murine CD1 Ib' (Mac-l + ) and CD1 1 b-populations. All of the blue cells segregated to the mouse CD1 1 b' (Mac-l ') population; only background staining (equivalent to nontransgenic control) wa5 observed in the mouse CD1 1 b-cells. Finally, to confirm that the P-gal staining reflected production of significant amounts of RNA by the promoter, we performed RNAse protection analysis of P-gal RNA (Fig 6) . We were able to observe high levels of @-gal RNA in CD1 Ib/ &gal macrophages, similar to the levels observed in a line of U937 cells stably transfected with a 0-gal reporter driven by a strong SV40 viral promoter (compare Fig 6, lanes 2 and 4) . In summary, all three founder lines expressed significant levels of reporter RNA in macrophages. This expression was observed consistently from generation to generation and in animals that were nearly 2 years old.
For The CD! Ih promoter is expressed predominantlv in mature myeloid cells. We observed relatively high levels of CD1 1 biThyl reporter RNA in macrophages compared with bone marrow (Fig 4) . After normalizing the intensity of the Northern blot bands to the copy number and 18s ribosomal bands, the transgene was found to express levels of RNA that were approximately two thirds of the endogenous mouse CD1 Ib in peritoneal macrophages, but only at approximately one tenth in bone marrow (Fig 4) . This finding suggested that the transgene was predominantly expressed in mature cells and not in progenitors. To further demonstrate this finding, bone marrow cells were separated by two-color FACS with antibodies recognizing the Thy 1.1 reporter and murine Gr-1. The Gr-1 MoAb recognizes a member of the Ly-6 gene family and is predominantly expressed on cells of the neutrophil lineage. 25 The intensity of staining with Gr-l can be correlated with the degree of maturation of the cells, with Gr-Ihi cells representing end-stage neutrophils.'" When CD1 1 bmhyl . l transgenic bone marrow cells were stained with Gr-I and Thy 1. I , many of the Gr-I + cells were negative for Thy1 . l expression (Fig 7B) . Examination of these Gr-I hi/ThyI .l'" cells by Wright-Giemsa staining showed that the majority were metamyelocytes, whereas almost all of the double-positive Gr-l h'iThyI .Ih' cells were mature polymorphonuclear granulocytes. We also performed two-color FACS of bone marrow cells with Thyl. I and murine CD1 l b (Mac-l) and observed a population of Mac-lhi/ Thy I. l'" cells in the bone marrow (Fig 7D) . The majority of these cells were immature monocytic or promyelocytic cells, whereas the double-positive Mac-l h'/rhyl. 1 h' population was predominantly composed of macrophages and mature neutrophils. These findings suggest that the human CD1 Ib promoter fragment used in these studies primarily directs expression to the mature myeloid compartment.
Each of the transgenic lines analyzed expressed significant reporter RNA in murine macrophages. Initial Northern blot analysis of the CD1 1 blThy1.I line indicated that transgene RNA was expressed only in those tissues that expressed endogenous mouse CD1 Ib (Fig 4) . However, additional FACS analysis was performed in peripheral blood and lymph nodes from mice derived from this founder (Figs 8 and 9) . In peripheral white blood cells, surface expression of the Thy I. I reporter was found in approximately 90% of Mac-1 + cells (Fig 8) . T cells from peripheral blood (Fig 8; similar results were obtained using surface T3 as a T-cell marker), lymph nodes (Fig 9) . spleen. thymus, or the peritoneal cavity were all negative for Thy I. 1 expression. However. a significant fraction of the B220+ B-cell population expressed the Thy 1. I reporter, both in peripheral blood and in lymph nodes (Figs 8 and 9 ). Further analysis showed that many of the Thy1 . l + B cells were CDS' (Lyl'; data not shown). In both &gal founders, we were unable to detect expression in purified CDS' B cells by Xgal staining, perhaps as a result of decreased sensitivity of this assay in lymphoid cells3' compared with FACS analysis, although in founder no. 33 we were able to detect &gal RNA in spleen (data not shown). In summary, we observed significant expression of reporter gene activity in mature myeloid cells and lesser expression in a subset of B cells. Northern blot analysis (Fig 4) indicates
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DISCUSSION
In these studies, we investigated the activity of the proximal CD1 lb promoter in transgenic mice. Although the number of independent founders in this study was relatively small, we believe that several conclusions can be drawn from the three founder lines studied in detail. First of all, the CD1 lb promoter is capable of driving high-level expression of a reporter gene in myeloid cells in transgenic mice at levels comparable to those of the endogenous CD1 l b promoter. Secondly, the activity of the -1.7-kb promoter is highest in mature myeloid cells, both in the neutrophilic and monocytic lineages. In one founder, we observed expression in the CD5' (Lyl+ or B-l) subset of B cells; previous studies have shown that this subset of B cells can express mouse or human CDllb1"."3'6; therefore, the activity of the C D l l b promoter may reflect the capability of these cells to express CD1 l b under certain circumstances. A number of transgenic studies have investigated the elements controlling myeloid gene expression, but to date none has been able to precisely define the elements required for myeloid specificity. For example, the proximal 1.5-kb of the gp91-phox gene, normally expressed at high levels in granulocytes, targeted reporter expression to a small subset of monocytic cells, but most monocytes and neutrophils did not express the tran~gene.~' In the case of human c-fe~/fps,'~ chicken lysozyme,39 or human cathepsin G,@ relatively large pieces of DNA (6 kb to 21.5 kb) were used that included the gene itself as the reporter. In each of these studies, the investigators reported high-level, properly regulated transgene expression, but the responsible regulatory elements have not yet been defined. A 5-kb portion of the monocytic monocyte colony-stimulating factor (M-CSF CSF-l) receptor promoter was reported to target major histocompatibility complex class I1 I-E to macrophages:' and the MRPS promoter was used to express bcl-2 in neutrophil^.^^
The expression patterns of the transgenes were not described in detail in either of these studies, but were stated to be specific for macrophages and neutrophils, respectively. CD1 fb, like most myeloid-specific genes, lacks a TATAA and previous studies using transient transfections in tissue culture cells have shown the role of two factors, Spl and PU. 1 (Spi-l), in the myeloid specificity of the CD1 l b promoter. '3.43 We are currently testing the effect of specific mutations of the binding sites for these two factors on the expression of the CD1 Ib promoter in transgenic mice. HowFor personal use only. on October 30, 2017. by guest www.bloodjournal.org From ever, it is interesting to note that of the myeloid genes that have been shown to function in transgenic studies to date, several of them, including CD1 lb,I3 the M-CSF re~eptor,'~ and the chicken lysozyme enhancer," have important functional PU.l sites, and that several of the others, including cfes and cathepsin G, have potential PU. l sites in their proximal promoter regions. Therefore, we suspect that PU.1, which appears to be critical for myeloid colony formation," will also be a critical factor in directing myeloid expression in transgenic studies.
Additional studies will be required to precisely define the elements required for myeloid expression of CDllb. However, our studies have shown that the -l .7-kb fragment can be used to express heterologous genes at high levels in myeloid cells and therefore should be useful in targeting heterologous genes in macrophages.
